Literature DB >> 29581111

Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.

S Deng1, W Lei2, G S de Hoog2,3,4,5, L Yang3, R G Vitale6, H Rafati7, M Seyedmousavi7, A Tolooe7, H van der Lee5, W Liao2, P E Verweij5, S Seyedmousavi8,7,9.   

Abstract

Our in vitro studies showed that a combination of amphotericin B and terbinafine had synergistic effects against the majority of melanized fungi associated with chromoblastomycosis (CBM) and similar infections, including those with Cladophialophora carrionii, Cladophialophora arxii, Exophialadermatitidis, Exophialaspinifera, Fonsecaea monophora, Fonsecaea nubica, Fonsecaea pedrosoi, and Phialophora verrucosa. This drug combination could provide an option for the treatment of severe or unresponsive cases of CBM, particularly in cases due to species of Fonsecaea and Cladophialophora.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  amphotericin B; chromoblastomycosis; combination therapy; melanized fungi; terbinafine

Mesh：

Substances：

Year:  2018        PMID： 29581111      PMCID： PMC5971613          DOI： 10.1128/AAC.00270-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  45 in total

1.  Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil.

Authors:  A K Gupta; P R Taborda; A D Sanzovo
Journal:  Med Mycol       Date:  2002-10       Impact factor: 4.076

2.  Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora.

Authors:  Jun-Min ZHANG; Li-Yan XI; Hui ZHANG; Zhi XIE; Jiu-Feng SUN; Xi-Qing LI; Sha LU
Journal:  Eur J Dermatol       Date:  2009-06-05       Impact factor: 3.328

3.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

4.  Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.

Authors:  Enrique Calvo; F Javier Pastor; Emilio Mayayo; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association.

Authors:  Vicente Sperb Antonello; Marcelo Campos Appel da Silva; Eduardo Cambruzzi; Dimas Alexandre Kliemann; Breno Riegel Santos; Flávio Queiroz-Telles
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2010 Nov-Dec       Impact factor: 1.846

6.  A case of chromoblastomycosis with an unusual clinical manifestation caused by Phialophora verrucosa on an unexposed area: treatment with a combination of amphotericin B and 5-flucytosine.

Authors:  S-G Park; S-H Oh; S-B Suh; K-H Lee; K-Y Chung
Journal:  Br J Dermatol       Date:  2005-03       Impact factor: 9.302

Review 7.  Treating chromoblastomycosis with systemic antifungals.

Authors:  Alexandro Bonifaz; Vanessa Paredes-Solís; Amado Saúl
Journal:  Expert Opin Pharmacother       Date:  2004-02       Impact factor: 3.889

8.  Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents.

Authors:  Tânia S Andrade; Luiz G M Castro; Ricardo S Nunes; Viviane M F Gimenes; Arlete E Cury
Journal:  Mycoses       Date:  2004-06       Impact factor: 4.377

9.  In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis.

Authors:  R G Vitale; M Perez-Blanco; G S De Hoog
Journal:  Med Mycol       Date:  2009-02       Impact factor: 4.076

Review 10.  Challenges in the therapy of chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Daniel Wagner de C L Santos
Journal:  Mycopathologia       Date:  2013-05-02       Impact factor: 2.574
View more
  4 in total

1.  The convoluted process of diagnosing pulmonary mycosis caused by Exophiala dermatitidis: a case report.

Authors:  Zhengtu Li; Jianli Tang; Jinping Zhu; Mingzhou Xie; Shaoqing Huang; Shaoqiang Li; Yangqing Zhan; Weiqi Zeng; Teng Xu; Feng Ye
Journal:  BMC Infect Dis       Date:  2022-05-04       Impact factor: 3.667

2.  Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction.

Authors:  Marcela Q Granato; Ingrid S Sousa; Thabatta L S A Rosa; Diego S Gonçalves; Sergio H Seabra; Daniela S Alviano; Maria C V Pessolani; André L S Santos; Lucimar F Kneipp
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

3.  Joining forces: Leveraging novel combination therapies to combat infections with eukaryotic pathogens.

Authors:  Rachel E Ham; Lesly A Temesvari
Journal:  PLoS Pathog       Date:  2020-12-31       Impact factor: 6.823

4.  Diagnosis of Cutaneous Chromoblastomycosis and Its Response to Amphotericin B Therapy: A Case Report.

Authors:  Furqan Ul Haq; Hamza Yunus; Rafia Mukhtiar; Ammar Ahmad; Romesa Akram; Sumaira Imran
Journal:  Cureus       Date:  2022-08-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.